PDCD1 and neoplasm: T lymphocytes, as the direct target of PD-1/PD-L1 blockade treatment, are known to be highly heterogeneous on the surface of T cells, and only a subset of T cells in a subpopulation of people are responsive to tumor-related antigens [21].